CXCR1 as a predictor of response to treatment with epidermal growth factor receptor therapeutic

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9823256
APP PUB NO 20140127689A1
SERIAL NO

14113783

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

There is provided a molecular marker CXCR1 for predicting response and survival in subjects afflicted with cancer who would benefit from treatment with and Epidermal Growth Factor Receptor (EGFR) targeted therapeutic.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE QUEEN'S UNIVERSITY OF BELFASTUNIVERSITY ROAD NORTHERN IRELAND BT1 1NN

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Oladipo, Olabode Belfast, GB 1 0
Waugh, David John James Bangor, GB 1 0
Wilson, Richard Belfast, GB 111 1778

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 21, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 21, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00